ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Three pharmaceutical firms faced setbacks in the clinical development of drugs that were anticipated to be major sellers. AstraZeneca said cediranib, a kinase inhibitor, was less effective than Genentech’s Avastin at treating colorectal cancer in a Phase II/III study. Cediranib had already failed to improve outcomes in lung cancer patients. Separately, Roche and Biogen Idec halted studies of ocrelizumab, a monoclonal antibody to treat rheumatoid arthritis, after a safety-monitoring board said the risks of the drug outweighed the benefits. And last, Pfizer and San Francisco-based Medivation said dimebon did not improve cognition or functioning in Alzheimer’s patients in a large Phase III trial. Medivation’s stock cratered 68% to settle at around $13.00 per share on the news.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X